I am Chief Scientific Officer and Academic Co-Founder of Quotient Therapeutics, starting full-time from January 2025. I have been the Head of Cancer, Ageing and Somatic Mutation at the Wellcome Sanger Institute since 2012, where my research program has focused on the genetic changes that cells acquire throughout life, and how these mutations are related to ageing, cancer and other disease processes. I received my Ph.D. from the University of Cambridge.